16/11/2021at 15:36

ALK execs sell shares worth USD 4m

The CEO and CFO at ALK have sold shares in the allergy firm for DKK 26.5m (USD 4m).

by marketwire, translated by daniel pedersen

Allergy firm ALK's CEO, Carsten Hellmann, and CFO, Søren Jelert, have sold shares worth DKK 26.5m (USD 4m), a company announcement states.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

ALK upgrades guidance after positive Q3 report
For subscribers
ALK still has two horses in adrenaline race
For subscribers
ALK CEO on peanut allergy competitors: "They might have been the first, but that does not necessarily mean they are the best"
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Både danskere og islændinge har nu multiresistente bakterier i kroppen efter at have spist antibiotikummet Dicillin. | Foto: Lægemiddelstyrelsen / Pr

Other

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

The Danish Medicines Agency seeks to bring the matter to European inspectors to increase awareness of potential problems in the future.

For subscribers

Pharma & biotech

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

For subscribers

Pharma & biotech

Zealand Pharma presents positive early-stage results for weight-loss candidate

For subscribers

Pharma & biotech

Genmab promotes senior VP for strategy to executive management

For subscribers

Medtech

Ambu wins European approval of two fifth-generation bronchoscopes

For subscribers

Antibiotic Dicillin has infected Danish and Icelandic patients Antibiotikummet Dicillin har smittet både danskere og islændinge med multiresistente bakterier, som patienterne sandsynligvis skal leve med resten af livet. | Foto: Lægemiddelstyrelsen / Pr

Pharma & biotech

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

For subscribers

Obesity drug hit makes Novo Nordisk more valuable than Nestle

The Danish drugmaker has climbed from seventh to second place of Europe’s most valuable firms in just two years.

For subscribers

Pharma & biotech

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

The study tested 25mg and 50mg doses, and both showed a higher efficacy after 52 weeks compared to 14mg.

For subscribers

Pharma & biotech

Novo Nordisk enters collaboration with AI-driven drug discovery company

Insilico Medicine has developed an AI-driven platform that will help the Danish drugmaker identify targets against liver fibrosis.

For subscribers

ALK execs sell shares worth USD 4m

Read the whole article

With your free trial you get:

Get full access for you and your coworkers

Related articles:

ALK upgrades guidance after positive Q3 report

ALK still has two horses in adrenaline race

ALK CEO on peanut allergy competitors: "They might have been the first, but that does not necessarily mean they are the best"

Sign up for our newsletter

Front page now

Denmark: Violation of good manufacturing practice is source of contaminated antibiotic

Analyst: New Novo Nordisk data sets the bar high for diabetes pills

Zealand Pharma presents positive early-stage results for weight-loss candidate

Genmab promotes senior VP for strategy to executive management

Ambu wins European approval of two fifth-generation bronchoscopes

Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market

Further reading

Obesity drug hit makes Novo Nordisk more valuable than Nestle

Novo Nordisk reaches primary endpoint in phase III study of oral semaglutide

Novo Nordisk enters collaboration with AI-driven drug discovery company

Jobs